CFA
ARCT icon

Carroll Financial Associates’s Arcturus Therapeutics ARCT Stock Holding History

Carroll Financial Associates’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$5K Hold
131
– – ﹤0.01% 1321
2021
Q3 		$6K Hold
131
– – ﹤0.01% 1333
2021
Q2 		$4K Hold
131
– – ﹤0.01% 1463
2021
Q1 		$5K Buy
+131
New +$7.81K ﹤0.01% 1355

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Carroll Financial Associates's ARCT Position: Q4 2021 in Review

Carroll Financial Associates held its Arcturus Therapeutics (ARCT) position steady in Q4 2021 at 131 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #1321.

Carroll Financial Associates first reported a position in ARCT in Q1 2021 and has held it in 4 quarters since. The position peaked at $6K in Q3 2021. 139 funds tracked by Wall St. Rank hold ARCT as of Q4 2021.

  • Carroll Financial Associates held 131 shares of Arcturus Therapeutics worth $5K as of Q4 2021.
  • Carroll Financial Associates left its Arcturus Therapeutics share count unchanged in Q4 2021.
  • Arcturus Therapeutics made up ﹤0.01% of Carroll Financial Associates's portfolio in Q4 2021, its #1321 holding.
  • Carroll Financial Associates first reported a position in Arcturus Therapeutics in Q1 2021 and has held it in 4 quarters since.
  • Carroll Financial Associates's Arcturus Therapeutics position peaked at $6K in Q3 2021.
  • 139 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2021.

Based on Carroll Financial Associates's 13F filing for Q4 2021, filed 6 Jan 2022.